Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.
On Friday, the fledgling field of psychedelic medicine suffered a major setback. The FDA declined to approve MDMA-assisted therapy for PTSD, instead asking the drugmaker Lykos Therapeutics to conduct ...
Thrombolytic therapy defines a group of medications that can dissolve blood clots. Healthcare professionals may administer them to treat a medical emergency, such as a heart attack or stroke. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results